Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Idelalisib

FDA-approved product (tablet, oral), marketed as Idelalisib, Zydelig.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Idelalisib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm
  • Neoplasm of mature B-cells
  • Non-Hodgkins lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phosphatidylinositol-3-kinase (pi3k) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Idelalisib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Idelalisib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

    NCT03576443 · start 2017-07-07

    Registered record
    Registry ID
    NCT03576443
    Conditions
    Diffuse Large B Cell Lymphoma
    Interventions
    Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-07-07
    Completion
    2021-09-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B Cell Lymphoma
    InterventionIdelalisib
    PhasePhase 2
    Registry statusCompleted

  • Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

    NCT02962401 · start 2017-03-07

    Registered record
    Registry ID
    NCT02962401
    Conditions
    Waldenstrom Macroglobulinemia
    Interventions
    Obinutuzumab; Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-07
    Completion
    2023-04-13
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenstrom Macroglobulinemia
    InterventionObinutuzumab; Idelalisib
    PhasePhase 2
    Registry statusCompleted

  • A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

    NCT02970318 · start 2017-02-02

    Registered record
    Registry ID
    NCT02970318
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Acalabrutinib (ACP-196); Rituximab; Idelalisib; Bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-02-02
    Completion
    2027-10-01
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionAcalabrutinib (ACP-196); Rituximab; Idelalisib; Bendamustine
    PhasePhase 3
    Registry statusActive not recruiting

  • Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

    NCT02968563 · start 2016-12-13

    Registered record
    Registry ID
    NCT02968563
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Tirabrutinib; Idelalisib; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-13
    Completion
    2021-01-14
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionTirabrutinib; Idelalisib; Obinutuzumab
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

    NCT02639910 · start 2016-11

    Registered record
    Registry ID
    NCT02639910
    Conditions
    Leukemia, Lymphocytic, Chronic, B-Cell; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Tafasitamab; Idelalisib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-11
    Completion
    2021-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Lymphocytic, Chronic, B-Cell; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionTafasitamab; Idelalisib; Venetoclax
    PhasePhase 2
    Registry statusCompleted

  • Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

    NCT02739360 · start 2016-05-04

    Registered record
    Registry ID
    NCT02739360
    Conditions
    Lymphoid Malignancies
    Interventions
    Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2016-05-04
    Completion
    2017-12-28
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoid Malignancies
    InterventionIdelalisib
    PhasePhase 4
    Registry statusTerminated

  • ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

    NCT02787369 · start 2016-05

    Registered record
    Registry ID
    NCT02787369
    Conditions
    Recurrent Chronic Lymphoid Leukemia
    Interventions
    ACY-1215; Ibrutinib; Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2016-05
    Completion
    2027-04
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Chronic Lymphoid Leukemia
    InterventionACY-1215; Ibrutinib; Idelalisib
    PhasePhase 1
    Registry statusActive not recruiting

  • Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib

    NCT02824159 · start 2016-04

    Registered record
    Registry ID
    NCT02824159
    Conditions
    Hematological Malignancies
    Interventions
    Blood samples for pharmacokinetics exploration; Imagery; Quality of life scale; Detection of adverse events; Saliva samples; Blood sample; Biological statement; Clinical examination
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-04
    Completion
    2020-12
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancies
    InterventionBlood samples for pharmacokinetics exploration; Imagery; Quality of life scale; Detection of adverse events +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Dose Optimization Study of Idelalisib in Follicular Lymphoma

    NCT02536300 · start 2016-01-14

    Registered record
    Registry ID
    NCT02536300
    Conditions
    Follicular Lymphoma
    Interventions
    Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2016-01-14
    Completion
    2022-09-27
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma
    InterventionIdelalisib
    PhasePhase 3
    Registry statusTerminated

  • Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis

    NCT02590588 · start 2016-01

    Registered record
    Registry ID
    NCT02590588
    Conditions
    Amyloidosis
    Interventions
    Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-01
    Completion
    2017-03-27
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis
    InterventionIdelalisib
    PhasePhase 2
    Registry statusTerminated

  • Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

    NCT02538614 · start 2015-12-29

    Registered record
    Registry ID
    NCT02538614
    Conditions
    Chronic Lymphocytic Leukemia (CLL)
    Interventions
    Idelalisib; BI 836826
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2015-12-29
    Completion
    2017-07-05
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia (CLL)
    InterventionIdelalisib; BI 836826
    PhasePhase 1
    Registry statusTerminated

  • Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

    NCT02603445 · start 2015-11-16

    Registered record
    Registry ID
    NCT02603445
    Conditions
    Follicular Lymphoma, Mantle Cell Lymphoma
    Interventions
    BCL201; Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11-16
    Completion
    2018-07-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma, Mantle Cell Lymphoma
    InterventionBCL201; Idelalisib
    PhasePhase 1
    Registry statusCompleted

  • Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab

    NCT02993536 · start 2015-11

    Registered record
    Registry ID
    NCT02993536
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Biospecimen Collection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2015-11
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionBiospecimen Collection
    PhaseNot recorded
    Registry statusWithdrawn

  • Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

    NCT02439138 · start 2015-10

    Registered record
    Registry ID
    NCT02439138
    Conditions
    Waldenstrom's Macroglobulinemia
    Interventions
    GS-1101
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-10
    Completion
    2016-04
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenstrom's Macroglobulinemia
    InterventionGS-1101
    PhasePhase 2
    Registry statusTerminated

  • Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

    NCT02258529 · start 2015-09-14

    Registered record
    Registry ID
    NCT02258529
    Conditions
    Follicular Lymphoma; Small Lymphocytic Lymphoma
    Interventions
    Idelalisib; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-09-14
    Completion
    2016-05-03
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma; Small Lymphocytic Lymphoma
    InterventionIdelalisib; Rituximab
    PhasePhase 2
    Registry statusTerminated